Clot Removal Procedure for Stroke With a Very Large Area of Damaged Brain
Compares clot removal plus medical care with medical care alone in stroke.
Plain-language title generated from the registry record
Registry title: Endovascular Treatment for Acute Large Vessel Occlusion With Ultra-Large Ischemic Core
Key facts
- Where
- Harbin, ChinaSee the site
Where in China
- he First Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Affiliated Hospital of Harbin Medical University
- Trial code
- NCT07791810
- Record updated
- 28 August 2026
- Original description
an investigator initiated, prospective, multicenter, randomized, open-label, blinded endpoint trial (PROBE)Read full original descriptionShow less
Endovascular Treatment for Acute Large Vessel Occlusion With Ultra-Large Ischemic Core: A Prospective, Multicenter, Randomized, Open-label, Blinded Endpoint Trial (LARGE CORE-MT)
an investigator initiated, prospective, multicenter, randomized, open-label, blinded endpoint trial (PROBE)
Inclusion: ≥18 years; Symptoms onset or Time last known well ≤ 24 h from randomization; Acute ischemic stroke due to an occlusion of the intracranial internal carotid artery, M1 or proximal M2 segment of the middle cerebral artery confirmed by CTA or MRA; NCCT or diffusion-weighted imaging (DWI) demonstrating ASPECTS ≤ 2 or infarct core volume (defined as rCBF <30% on CTP) ≥ 100 mL; Selection imaging performed ≤ 3 hours before randomization; Pre-stroke mRS 0 - 1; Informed consent form was signed.
Exclusion: Current treatment with direct thrombin inhibitors or factor Xa inhibitors; Concomitant malignancy or other conditions with life expectancy under 6 months; Prior endovascular attempt for this stroke; Evidence of intracranial hemorrhage on CT/MRI, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, or subdural/epidural hemorrhage; Patients with severe organ failure (cardiac, pulmonary, renal, or hepatic); Known coagulopathy, with international normalized ratio (INR) >1.7 or platelet count <100×10⁹/L; Cerebral midline shift or herniation, or other ventricular mass effect with midline shift as confirmed on CT/MRI; Bilateral anterior circulation or acute multi-vessel occlusion involving both anterior and posterior circulation, confirmed by CTA or MRA; Blood pressure >185/110 mmHg and is refractory to medicine; Female who is known to be pregnant; Currently participation in another clinical study; Other circumstances that the investigator considers inappropriate for participation.